Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 75

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 75
---
 the executive’s target bonus for the year of termination; and payment of COBRA premiums for up to 18 months for Dr. Seehra or up to 12 months for our other NEOs. Jasbir Seehra, Ph.D. As further described under “Compensation Discussion and Analysis — Elements of Our 2024 Executive Compensation Program — Equity Compensation” in this Proxy Statement, Dr. Seehra was granted a performance-vesting option in February 2024. The option is subject to acceleration under specified conditions. For purposes of the option, involuntary termination refers to termination of continuous service without cause (and not due to death or disability) or resignation for good reason. Cause, disability and good reason are defined in Dr. Seehra’s employment agreement. The change in control period refers to the time period beginning immediately before and terminating two years following a change in control (as defined in the 2020 Plan). • In the event of a change in control prior to vesting of any portion of the option and during Dr. Seehra’s continuous service, if the surviving or acquiring corporation does not assume, continue or substitute the option, the option will accelerate in full. • In the event of Dr. Seehra’s involuntary termination outside of the change in control period and prior to vesting of any portion the option, the option will remain outstanding and eligible to vest for 12 months, after which it will terminate (subject to satisfaction of a release condition). • In the event of Dr. Seehra’s involuntary termination during the change in control period and prior to vesting of any portion of the option, the option will accelerate in full (subject to satisfaction of a release condition). • After the first vesting tranche, if either (i) a change in control occurs during Dr. Seehra’s continuous service or (ii) Dr. Seehra experiences an involuntary termination, the option will be treated consistently with other time-vesting options in accordance with the 2020 Plan and Dr. Seehra’s employment agreement. The table below shows estimates of the compensation payable to each of our NEOs upon their termination of employment with the Company and/or upon a change of control, calculated as if the triggering event had occurred effective December 31, 2024. The actual amounts due to any one of the NEOs upon termination of employment can only be determined at the time of the termination. There can be no assurance that a termination or change of control would produce the same or